Valuation : Carmat SA

Market Cap 6.15M 7.14M 5.79M 5.27M 9.87M 680M 9.9M 68.58M 26.51M 346M 26.82M 26.24M 1.1B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 68.85M 55.79M 50.83M 95.1M 6.55B 95.48M 661M 256M 3.34B 259M 253M 10.57B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.1
Extreme 0.0962
0.16
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
40.06
Manager TitleAgeSince
Chief Executive Officer 55 31/08/2016
Director of Finance/CFO - 11/12/2018
Chief Tech/Sci/R&D Officer - 31/03/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 01/01/2017
Director/Board Member 79 19/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
13/03/25 Sell

Chairman

1,343,333 2.3347%
13/03/25 Buy

Chairman

1,343,333 2.3347%
29/05/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-24.77%-98.53% 7.08M
-0.50%-11.12%-28.52%-8.66% 106B
-0.46%-2.90%-27.71%-4.31% 11.68B
-2.77%-2.99%+99.90%+130.29% 10.6B
-2.18%-4.26%-54.99%-71.10% 4.08B
-1.02%-2.40%-28.53%+34.56% 2.42B
-3.34%-8.43% - - 1.88B
+0.36%+6.80%-15.75%-70.31% 1.92B
-1.11%-1.91%-23.15%-28.32% 1.55B
Average -1.27%-2.50%-12.94%-14.55% 15.53B
Weighted average by Cap. -0.72%-9.09%-19.12%+0.21%

Financials

2023 2024
Net sales 3.84M 4.46M 3.61M 3.29M 6.16M 424M 6.18M 42.82M 16.55M 216M 16.74M 16.38M 685M 7.34M 8.53M 6.92M 6.3M 11.79M 812M 11.84M 81.96M 31.68M 414M 32.05M 31.35M 1.31B
Net income -53.87M -62.6M -50.72M -46.22M -86.47M -5.96B -86.82M -601M -232M -3.03B -235M -230M -9.61B -51.4M -59.73M -48.39M -44.09M -82.5M -5.68B -82.83M -574M -222M -2.9B -224M -219M -9.17B
Net Debt 49.64M 57.68M 46.74M 42.58M 79.68M 5.49B 79.99M 554M 214M 2.8B 217M 212M 8.86B 53.1M 61.71M 50M 45.56M 85.24M 5.87B 85.58M 593M 229M 2.99B 232M 227M 9.48B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!